Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sleecap
- Development stage
- Unknown
- Lead developer
- Juvenor Pharmaceuticals
- Administration
- Oral
01
Overview
**Sleecap** is an oral polyherbal phytomedicine capsule marketed for sleep disturbances, particularly insomnia. The marketed formulation contains extracts of *Nardostachys jatamansi* (jatamansi), *Convolvulus pluricaulis* (shankhapushpi), *Withania somnifera* (ashwagandha), and *Rauwolfia serpentina* (sarpagandha). Juvenor Pharmaceuticals' product information describes a sedative and stress-relieving effect and states that the product acts on the gamma-aminobutyric acid type A receptor. Piramal developed the phytomedicine, with Juvenor Pharmaceuticals marketing Piramal Phytocare products.
- Brand names
- Sleecap
02
Targets
GABAA (Gamma-aminobutyric acid receptor)
Beyond the preview
Go deeper on Sleecap.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sleecap.